Search for content, post, videos

Genovis receives USD 1 million in milestone compensation

The milestone compensation is related to achieved development goals for the Xork enzyme that Genovis has licensed for therapeutic applications, primarily as a potential pre-treatment in gene therapy but also for autoimmune diseases.

Xork was discovered in a subset of streptococci that do not infect humans and the preclinical data generated to date clearly show that there are very low levels of antibodies to the enzyme in humans and that it retains its IgG specific activity in serum.

Photo of Fredrik Olsson, CEO, Genovis: Christian Andersson/Genovis